Nose-to-brain/spinal cord delivery kinetics of liposomes with different surface properties

被引:38
|
作者
Kurano, Takumi [1 ]
Kanazawa, Takanori [1 ,2 ]
Ooba, Aoi [1 ]
Masuyama, Yudai [1 ]
Maruhana, Nao [1 ]
Yamada, Mayu [1 ]
Iioka, Shingo [2 ]
Ibaraki, Hisako [3 ]
Kosuge, Yasuhiro [1 ]
Kondo, Hiromu [2 ]
Suzuki, Toyofumi [1 ]
机构
[1] Nihon Univ, Sch Pharm, 7-7-1 Narashinodai, Funabashi, Chiba 2748555, Japan
[2] Univ Shizuoka, Sch Pharmaceut Sci, 52-1 Yada,Suruga Ku, Shizuoka 4228526, Japan
[3] Tokyo Univ Pharm & Life Sci, Sch Pharm, 1432-1 Horinouchi, Hachioji, Tokyo 1920392, Japan
关键词
Nose-to-brain; Liposome; Nanocarrier; Pharmacokinetics; Brain; Spinal cord; INTRANASAL DELIVERY; BRAIN DELIVERY; QUANTITATIVE-ANALYSIS; NANOPARTICLES; TRANSPORT; CHARGE; DOXORUBICIN; ROUTE; PEG;
D O I
10.1016/j.jconrel.2022.03.017
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The administration of liposomes via nose-to-brain delivery is expected to become a strategy for efficient drug delivery to the central nervous system. Efficient nose-to-brain delivery and the kinetics of drugs administered in this manner depend on the properties of liposomes. However, there is a lack of basic knowledge of which liposomes are suitable for this purpose. Here, a qualitative study of intranasally administered liposomes (positively charged, neutral, and negatively charged, with or without polyethylene glycol [PEG] modification; particle size < 100 nm) was performed to elucidate their dynamics in the brain and spinal cord. Additionally, a quantitative investigation was performed to ascertain their distribution in each part of the brain and spinal cord. The effects of liposome surface charge and PEG modification on the kinetics and distribution post intranasal administration were investigated via two experiments. Qualitative evaluation was performed via ex vivo observation after intranasal administration of fluorescently labeled liposomes. Neutral PEG-modified liposomes were distributed throughout the brain and spinal cord 60 min after administration, and the fluorescence intensity increased with time. By contrast, non-PEG-modified neutral liposomes showed particularly strong fluorescence in the olfactory bulb, and the fluorescence was localized in the anterior part of the brain. Positively charged liposomes showed low fluorescence around the lateral part of the brain and lumbar spinal cord 60 min after administration. Low fluorescence was observed in the whole brain and spinal cord, with strong fluorescence being observed in the olfactory bulb after 120 min of administration. Negatively charged liposomes showed no fluorescence at 60 min after administration, but low fluorescence was observed throughout the brain and spinal cord 120 min after administration. We quantified the radioactivity in the brain and spinal cord after intranasal administration of radioisotope-labeled liposomes. Neutral liposomes showed the highest distribution by area under the drug concentration-time curve (AUC60-120) in the brain and spinal cord compared to other liposomes. Compared with negatively charged liposomes, positively charged liposomes had a higher distribution in the olfactory bulb and forebrain, while negatively charged liposomes had a higher distribution in the hindbrain and bulbospinal tract cord. In addition, the distribution of PEG-modified neutral liposomes in the brain and spinal cord was significantly enhanced compared to that of non-PEG-modified neutral liposomes after 90 min of intranasal administration. These results indicate that surface charge and PEG modification strongly affect the efficiency of nose-to brain delivery kinetics, and that PEG-modified neutral liposomes are excellent carriers for drug delivery to a wide area of the brain and spinal cord.
引用
收藏
页码:225 / 234
页数:10
相关论文
共 50 条
  • [1] Cachexia: Pathophysiology and Ghrelin Liposomes for Nose-to-Brain Delivery
    de Barros, Cecilia T.
    Rios, Alessandra C.
    Alves, Thais F. R.
    Batain, Fernando
    Crescencio, Kessi M. M.
    Lopes, Laura J.
    Zielinska, Aleksandra
    Severino, Patricia
    Mazzola, Priscila G.
    Souto, Eliana B.
    Chaud, Marco, V
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (17) : 1 - 16
  • [2] Nose-to-Brain Delivery
    Wang, Zian
    Xiong, Guojun
    Tsang, Wai Chun
    Schatzlein, Andreas G.
    Uchegbu, Ijeoma F.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2019, 370 (03): : 593 - 601
  • [3] Nose-to-Brain Delivery
    Giunchedi, Paolo
    Gavini, Elisabetta
    Bonferoni, Maria Cristina
    PHARMACEUTICS, 2020, 12 (02)
  • [4] Nose-to-brain delivery of tacrine
    Jogani, Viral V.
    Shah, Pranav J.
    Mishra, Pushpa
    Mishra, Anil Kumar
    Misra, Ambikanandan R.
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2007, 59 (09) : 1199 - 1205
  • [5] Nose-to-brain delivery of biologics
    Schwarz, Bettina
    Merkel, Olivia M.
    THERAPEUTIC DELIVERY, 2019, 10 (04) : 207 - 210
  • [6] Development of coated liposomes loaded with ghrelin for nose-to-brain delivery for the treatment of cachexia
    Salade, Laurent
    Wauthoz, Nathalie
    Deleu, Magali
    Vermeersch, Marjorie
    De Vriese, Carine
    Amighi, Karim
    Goole, Jonathan
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2017, 12 : 8531 - 8543
  • [7] Nanoemulsions for "Nose-to-Brain" Drug Delivery
    Bonferoni, Maria Cristina
    Rossi, Silvia
    Sandri, Giuseppina
    Ferrari, Franca
    Gavini, Elisabetta
    Rassu, Giovanna
    Giunchedi, Paolo
    PHARMACEUTICS, 2019, 11 (02):
  • [8] Nose-to-brain peptide delivery - The potential of nanotechnology
    Samaridou, Eleni
    Alonso, Maria Jose
    BIOORGANIC & MEDICINAL CHEMISTRY, 2018, 26 (10) : 2888 - 2905
  • [9] SLN approach for nose-to-brain delivery of alprazolam
    Alok Pratap Singh
    Shailendra K. Saraf
    Shubhini A. Saraf
    Drug Delivery and Translational Research, 2012, 2 : 498 - 507
  • [10] SLN approach for nose-to-brain delivery of alprazolam
    Singh, Alok Pratap
    Saraf, Shailendra K.
    Saraf, Shubhini A.
    DRUG DELIVERY AND TRANSLATIONAL RESEARCH, 2012, 2 (06) : 498 - 507